Diametric Capital’s Solid Biosciences SLDB Stock Holding History

Diametric Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,294	Closed	-$201K	–	152
2019 Q3	$201K	Buy	+1,294	New	+$146K	0.17%	90

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Diametric Capital's SLDB Position: Q4 2019 in Review

Diametric Capital sold out of Solid Biosciences (SLDB) in Q4 2019, closing a stake of 1,294 shares — an estimated $201K sold.

Diametric Capital first reported a position in SLDB in Q3 2019 and held it in 1 quarter. The position peaked at $201K in Q3 2019. 69 funds tracked by Wall St. Rank hold SLDB as of Q4 2019.

Diametric Capital reported no remaining Solid Biosciences position as of Q4 2019 after selling out during the quarter.
Diametric Capital sold 1,294 Solid Biosciences shares in Q4 2019, an estimated $201K.
Diametric Capital first reported a position in Solid Biosciences in Q3 2019 and held it in 1 quarter.
Diametric Capital's Solid Biosciences position peaked at $201K in Q3 2019.
69 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2019.

Based on Diametric Capital's 13F filing for Q4 2019, filed 14 Feb 2020.